Renin-Angiotension System Blockade as Prevention of Hearing Loss
Approved Research ID: 92843
Approval date: December 22nd 2022
Up to 1 in 12 people worldwide is estimated to suffer from hearing loss. Although a common condition, current treatments for hearing loss are relatively limited, restricted to use of hearing aids, cochlear implants, or other forms of sound amplification. Due to the large number of individuals affected by hearing loss and the current limitations in treatment, it is important to research new ways to prevent or treat hearing loss.
Recent research has suggested that some medications with anti-inflammatory properties can help protect against multiple forms of hearing loss. In particular, some studies have found that certain classes of commonly prescribed anti-hypertensive medications called Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) have protective effects against a variety of inflammatory diseases. It is possible that the use of these medications could help protect the delicate blood vessels that feed the inner ear from inflammation and damage, which would help to prevent hearing loss.
Our research project plans to look at large groups of individuals with hypertension who are being treated with these ACEi and ARB medications and assess how many of them have diagnoses related to hearing loss. We will compare them with individuals with hypertension who are being treated with other anti-hypertensive medications to see if there is a difference in the frequency of hearing loss between these groups. This will help us know if the use of ACEi or ARB medications are associated with a lower frequency of hearing loss. This information would help educate further research to develop treatments to prevent hearing loss.